Skip to main content
. 2016 Jul 21;4:151. doi: 10.3389/fpubh.2016.00151

Table 1.

The 1-, 2-, and 5-year survivala for malignant brain and CNS tumors by histology and country.

USb
Taiwan
1-Year 2-Year 5-Year 1-Year 2-Year 5-Year


Histology N Rate (95% CI) Rate (95% CI) Rate (95% CI) N Rate (95% CI) Rate (95% CI) Rate (95% CI)
Neuronal and mixed neuronal glial tumors 82 94.7 (86.6–98.0) 85.7 (74.9–92.0) 71.3 (57.3–81.5) 63 87.3 (76.2–93.4) 71.4 (58.6–80.9) 50.7 (37.4–62.6)
Ependymal tumors 1,781 93.8 (92.6–94.9) 89.3 (87.7–90.8) 82.0 (79.8–84.1) 177 88.1 (82.4–92.1) 83.1 (76.7–87.8) 69.0 (61.3–75.4)
Oligodendroglioma 2,018 93.8 (92.6–94.8) 89.6 (88.1–90.9) 78.7 (76.5–80.8) 283 91.9 (88.0–94.5) 83.0 (78.1–86.9) 70.3 (64.5–75.4)
Germ cell tumors, cysts, and heterotopias 556 91.5 (88.8–93.6) 89.0 (86.0–91.5) 83.8 (79.8–87.0) 263 92.0 (88.0–94.7) 87.1 (82.4–90.6) 81.2 (75.7–85.6)
Oligoastrocytic tumors 1,345 88.1 (86.2–89.8) 77.8 (75.3–80.1) 62.8 (59.5–65.9) 194 89.7 (84.5–93.2) 77.3 (70.8–82.6) 61.9 (54.3–68.6)
Anaplastic oligodendroglioma 797 83.6 (80.8–86.1) 72.2 (68.8–75.4) 54.6 (50.4–58.6) 150 82.7 (75.6–87.9) 62.0 (53.7–69.2) 35.4 (27.3–43.7)
Embryonal tumors 1,738 81.6 (79.7–83.4) 72.5 (70.2–74.7) 60.9 (58.1–63.5) 342 80.7 (76.1–84.5) 69.3 (64.1–73.9) 54.1 (48.6–59.4)
Meningioma 684 79.3 (76.0–82.2) 70.9 (67.2–74.3) 59.4 (55.2–63.4) 299 81.9 (77.1–85.9) 66.9 (61.2–71.9) 49.9 (43.9–55.6)
Nerve sheath tumors 117 78.3 (69.4–84.9) 71.4 (61.8–79.0) 68.2 (58.3–76.2) 23 60.9 (38.3–77.4) 56.5 (34.3–73.8) 52.2 (30.5–70.0)
Astrocytoma excluding GBM and AA 4,101 73.4 (72.0–74.8) 62.9 (61.3–64.4) 48.8 (47.0–50.6) 929 76.0 (73.1–78.6) 63.6 (60.4–66.6) 47.8 (44.5–51.1)
AA 2,313 63.2 (61.1–65.1) 44.8 (42.6–47.0) 27.7 (25.5–29.9) 447 67.8 (63.2–71.9) 45.0 (40.3–49.5) 22.1 (18.1–26.3)
Glioma malignant, NOS 2,821 62.5 (60.6–64.3) 51.9 (49.9–53.8) 44.6 (42.6–46.7) 293 63.8 (58.0–69.0) 43.3 (37.6–48.9) 32.5 (27.1–38.0)
CNS lymphoma 2,898 51.4 (49.5–53.2) 42.6 (40.7–44.5) 31.5 (29.5–33.4) 347 63.1 (57.8–68.0) 47.6 (42.2–52.7) 22.3 (17.8–27.1)
GBM 19,893 37.5 (36.8–38.2) 15.7 (15.2–16.3) 5.0 (4.6–5.4) 2,045 50.3 (48.1–52.4) 24.0 (22.1–25.8) 9.8 (8.5–11.2)
All values 41,144 56.5 (56.0–57.0) 41.1 (40.6–41.6) 30.0 (29.5–30.5) 5,855 68.1 (66.9–69.3) 49.9 (48.6–51.2) 34.3 (33.1–35.6)

aRates are sorted from the largest to the smallest based on the 1-year US data.

bEstimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: incidence – SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, November 2013 Sub (1973–2011 varying) – Linked To County Attributes – Total US, 1969–2012 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2014, based on the November 2013 submission.

AA, anaplastic astrocytoma; CI, confidence interval; CNS, central nervous system; GBM, glioblastoma; NOS, not otherwise specified.